Drug intelligence / Profile preview

SYN-001

Development stage: Preclinical
Lead developer: Synergys Biotherapeutics
Modality: Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

SYN-001 is a novel antibody fusion therapeutic developed by Synergys Biotherapeutics in collaboration with the University of Miami/Sylvester Comprehensive Cancer Center. It is designed for the treatment of Triple Negative Breast Cancer (TNBC). The drug's mechanism of action involves blocking vasculogenic mimicry (VM), exhibiting anti-angiogenic activity, and retaining antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is currently in preclinical development, with a Phase I/Phase II Fast-Track grant from the National Cancer Institute (NCI) supporting its progression towards clinical trials.

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on SYN-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYN-001.

Explore the full profile